Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors.

Journal of cancer research and clinical oncology - 7 Mar 2026

Jörg Inna, Chronas Dimitrios

Abstract excerpt

Premenopausal women carrying a BRCA1 or BRCA2 mutation are frequently advised to undergo risk-reducing bilateral salpingo-oophorectomy (BSO) to lower their significantly increased lifetime risk of ovarian cancer. However, this procedure induces abrupt estrogen deprivation, resulting in premature menopause with well-documented consequences including vasomotor symptoms (e.g., hot flashes, night sweats), urogenital...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormone Replacement Therapy

Share to Ovarian Neoplasms

Share to Salpingo-oophorectomy

Share to Survivors

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41793502
DOI: 10.1007/s00432-026-06425-9
PMCID: PMC12967752

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors.PMID 41793502Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Semantic proximity Read ↗

BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.Semantic proximity Read ↗

Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.Semantic proximity Read ↗

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.Semantic proximity Read ↗

Challenging and complex decisions in the management of the BRCA mutation carrier.Semantic proximity Read ↗

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Hereditary Women's Cancer: Management and Risk-Reducing Surgery.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.